Approximately 80
percent of TSC patients develop seizures between birth and age 3. The new EEG biomarker,
the first of its kind in TSC patients, presents as an abnormality in the EEG
called an epileptiform discharge. In the study, all infants with the biomarker
developed seizures within two to three months.
"The earlier
seizures are recognized and treated, the better the developmental outcomes for
children with TS," said E. Martina Bebin, M.D., professor in the
Department of Neurology at UAB and the study's senior author. "The
development of this predictive biomarker may provide a critical window of opportunity
for families and medical providers to initiate treatment at seizure onset, with
potentially a positive impact on the infant's developmental outcome."
The study, conducted
at five medical centers across the United States, examined 40 children with a
diagnosis of TSC.
The presence of the
biomarker means families will need to learn the identifying signs of seizures
and begin to involve a neurologist in their child's care prior to actual
seizure onset. Bebin says the study reinforces the idea that EEG should be done
at time of diagnosis for TSC, and repeated on a regular basis. The study
conducted EEG every six weeks.
"The results of
this study not only support the importance of that initial EEG but also the
importance of subsequent EEGs in monitoring the development of seizuresand epileptiform discharges," Bebin said. "Our study
demonstrates the feasibility and importance of close EEG surveillance in
infants with TSC for predicting those who will subsequently develop
epilepsy."
Bebin says further studies
are needed to better understand the relationship between various therapeutic
agents and the biomarker, along with determination of the optimal timeframe in
which to begin therapy.
Joyce Y. Wu, Jurriaan
M. Peters, Monisha Goyal, Darcy Krueger, Mustafa Sahin, Hope Northrup, Kit Sing
Au, Gary Cutter, E. Martina Bebin. Clinical
Electroencephalographic Biomarker for Impending Epilepsy in Asymptomatic
Tuberous Sclerosis Complex Infants. Pediatric
Neurology. Published online: September 23 2015
Abstract
Background
We assessed the
clinical utility of routine electroencephalography (EEG) in the prediction of
epilepsy onset in asymptomatic infants with tuberous sclerosis complex.
Methods
This multicenter
prospective observational study recruited infants younger than 7 months,
seizure-free and on no antiepileptic drugs at enrollment, who all underwent
serial physical examinations and video EEGs throughout the study. Parental
education on seizure recognition was completed at the time of initial
enrollment. Once seizure onset occurred, standard of care was applied, and
subjects were followed up until 24 months.
Results
Forty patients were
enrolled, 28 older than 12 months with completed EEG evaluation at the time of
this interim analysis. Of those, 19 (67.8%) developed seizures. Epileptic
spasms occurred in 10 (52.6%), focal seizures in five (26.3%), generalized
tonic-clonic seizure in one (5.3%), and a combination of epileptic spasms and
focal seizures in three (15.7%). Fourteen infants (73.6%) had the first
emergence of epileptiform abnormalities on EEG at an average age 4.2 months,
preceding seizure onset by a median of 1.9 months. Hypsarrhythmia or modified
hypsarrhythmia was not found in any infant before onset of epileptic spasms.
All children with epileptiform discharges subsequently developed epilepsy (100%
positive predictive value), and the negative predictive value for not
developing epilepsy after a normal EEG was 64%.
Conclusions
Serial routine EEGs in infants with tuberous
sclerosis complex is a feasible strategy to identify individuals at high risk
for epilepsy. The most frequent clinical presentation was epileptic spasms
followed by focal seizures, and then a combination of both seizure types.
From the article, Clinical Electroencephalographic Biomarker for Impending Epilepsy in Asymptomatic Tuberous Sclerosis Complex Infants
ReplyDeleteTable 3
Statistical Analysis Summary
Clinical seizure No Clinical Seizure
Epileptiform discharges 14 0
No epileptiform discharges/Normal electroencephalography 5 9
Sensitivity (%) Specificity (%) Positive Predictive Value (%) Negative Predictive Value (%)
73.7 100 100 64
The positive predictive value (PPV), or how often the presence of a biomarker can correctly predict the disease in a population, can be determined from the ratio of true positives (those subjects with both abnormal EEG and subsequent seizures) to the sum of true positives and false positives (those with abnormal EEG and no subsequent seizures). The corresponding PPV ( Table 3 ) for the presence of epileptiform activity on an EEG preceding the development of clinical seizure onset in infants with TSC is then 14/(14 + 0), or 100% CI (76.8%, 100.0%).
Similarly, the negative predictive value (NPV), or how often the absence of a biomarker can correctly predict the nondisease state in a population, is determined from the ratio of true negatives (subjects with both normal EEG and no seizures) to the sum of true negatives and false negatives (subjects with normal EEG but subsequently developing seizures). The corresponding NPV ( Table 3 ) of the absence of epileptiform activity on the EEG and no subsequent epilepsy in infants with TSC is then 9/(9 + 5), or 64.3% CI (35.1%, 87.2%).
The other EEG findings of focal or generalized slowing, attenuation, hypsarrhythmia or modified hypsarrhythmia, and ictal events did not consistently precede the onset of clinical seizures, and none reached statistical significance.